Cardiac Markers Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product Type (Troponins, Myoglobin, Creatine Kinase-MB, B-type Natriuretic Peptide, Others), By Testing Type (Laboratory based Testing, Point of care testing), By Application (Acute Coronary Syndrome, Myocardial Infarction, Congestive Heart Failure, Others) and Region Forecast 2020-2031

Cardiac Markers Market size was valued at US$ 14,783.2 million in 2024 and is expected to reach US$ 42,033.3 million by 2031, growing at a significant CAGR of 16.1% from 2025-2031. Moreover, the USA Cardiac Markers Market is projected to grow significantly, reaching an estimated value of US$ 15,965.1 Million by 2031. The market encompasses products and solutions designed to detect specific proteins and enzymes released into the bloodstream during cardiac stress or damage. These markers play a crucial role in diagnosing heart-related conditions, guiding treatment decisions, and monitoring patient outcomes. Key cardiac markers include troponin, CK-MB, myoglobin, and BNP, each offering distinct clinical insights into cardiac function and injury.

The market is driven by the increasing burden of cardiovascular diseases worldwide, coupled with growing awareness about early diagnosis and preventive care. Continuous advancements in diagnostic technologies, combined with the rising adoption of point-of-care testing devices, are enhancing the speed and accuracy of cardiac marker testing. Furthermore, government initiatives to reduce cardiovascular mortality and investments in healthcare infrastructure are propelling market growth. While developed regions dominate the market, rapid urbanization and healthcare improvements in developing countries are creating new growth opportunities.

Key Developments:

• In January 2024, Roche Diagnostics announced the global launch of its next-generation high-sensitivity cardiac troponin T (hs-cTnT) assay, designed for faster and more accurate detection of myocardial infarction in emergency settings, helping clinicians make quicker decisions with improved confidence.
• In November 2023, Abbott Laboratories received FDA clearance for its i-STAT TBI plasma test, which includes advanced cardiac marker detection capabilities, expanding the use of portable point-of-care devices for rapid cardiac and neurological diagnostics in both hospital and field environments.

Cardiac Markers Market Segmentation:

Based on the product type:

• Troponins
• Myoglobin
• Creatine Kinase-MB
• B-type Natriuretic Peptide
• Others

Based on product type, troponins are anticipated to lead the cardiac markers market, driven by their exceptional diagnostic accuracy and clinical reliability in detecting myocardial infarction. Troponins, particularly Troponin I and Troponin T, are highly specific to cardiac muscle damage and are recognized as the gold standard biomarkers for acute coronary syndromes. Their ability to detect even minor cardiac injuries with high sensitivity makes them the preferred choice among healthcare providers worldwide. The growing prevalence of heart attacks and rising emergency admissions further boost the demand for rapid troponin testing, particularly in point-of-care settings. Continuous advancements in high-sensitivity troponin assays have enhanced early detection capabilities, allowing for quicker medical intervention and reducing patient mortality rates.

Additionally, their widespread inclusion in global clinical guidelines for cardiac care reinforces their dominant market position. As healthcare systems increasingly emphasize early diagnosis and precision medicine, troponins are expected to remain the leading product segment in the market.

Based on the testing type:

• Laboratory based Testing
• Point of care testing

Based on testing type, laboratory-based testing is anticipated to hold the largest share in the cardiac markers market. This dominance is primarily driven by the high accuracy, reliability, and advanced analytical capabilities offered by laboratory settings. Laboratory-based testing allows for comprehensive cardiac marker panels, including multiple biomarkers such as troponins, CK-MB, and BNP, to be analyzed simultaneously with precise results. Hospitals and large diagnostic centers prefer laboratory-based testing for critical and confirmatory diagnostics, especially in complex cardiac cases requiring thorough evaluation. Additionally, the growing number of cardiovascular diagnostic procedures and routine screening tests performed in hospitals and clinical laboratories continues to drive demand for this segment.

Technological advancements in laboratory analyzers, automated systems, and the integration of high-sensitivity assays further strengthen the efficiency and speed of lab-based testing. While point-of-care testing is growing rapidly, laboratory-based testing remains the gold standard for its accuracy, making it the leading testing type in the market.

Based on the Application:

• Acute Coronary Syndrome
• Myocardial Infarction
• Congestive Heart Failure
• Others

Based on application, myocardial infarction is anticipated to dominate the cardiac markers market. This leading position is primarily attributed to the high global prevalence and growing incidence of heart attacks, which remain a leading cause of death worldwide. Cardiac markers, especially troponins, play a crucial role in the early and accurate diagnosis of myocardial infarction, enabling rapid medical intervention and significantly improving survival rates. The increasing number of emergency room visits due to chest pain and suspected heart attacks is further driving the demand for efficient biomarker testing. Healthcare systems across the globe are prioritizing the adoption of high-sensitivity assays to detect even the smallest signs of myocardial injury, allowing for timely and precise treatment decisions.

Additionally, clinical guidelines universally recommend cardiac biomarker testing as an essential diagnostic step in suspected myocardial infarction cases. With continued advancements in diagnostic technologies and the growing burden of cardiac emergencies, myocardial infarction remains the key application area leading market growth.